X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA NOVARTIS PLETHICO PHARMA/
NOVARTIS
 
P/E (TTM) x -1.1 295.9 - View Chart
P/BV x 0.0 25.2 0.1% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PLETHICO PHARMA   NOVARTIS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
NOVARTIS
Mar-17
PLETHICO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs395855 46.2%   
Low Rs31666 4.7%   
Sales per share (Unadj.) Rs604.4219.0 275.9%  
Earnings per share (Unadj.) Rs32.519.1 170.1%  
Cash flow per share (Unadj.) Rs51.320.3 252.9%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs473.6307.0 154.3%  
Shares outstanding (eoy) m34.0829.96 113.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.5 10.2%   
Avg P/E ratio x6.639.8 16.5%  
P/CF ratio (eoy) x4.237.5 11.1%  
Price / Book Value ratio x0.52.5 18.2%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m7,26222,779 31.9%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m1,5961,393 114.6%   
Avg. sales/employee Rs ThNM9,736.2-  
Avg. wages/employee Rs ThNM2,066.8-  
Avg. net profit/employee Rs ThNM849.0-  
INCOME DATA
Net Sales Rs m20,5986,562 313.9%  
Other income Rs m386702 55.1%   
Total revenues Rs m20,9847,264 288.9%   
Gross profit Rs m2,818259 1,088.3%  
Depreciation Rs m64236 1,789.1%   
Interest Rs m1,5937 22,127.8%   
Profit before tax Rs m969917 105.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138345 -40.1%   
Profit after tax Rs m1,107572 193.4%  
Gross profit margin %13.73.9 346.7%  
Effective tax rate %-14.337.6 -38.0%   
Net profit margin %5.48.7 61.6%  
BALANCE SHEET DATA
Current assets Rs m18,8779,731 194.0%   
Current liabilities Rs m11,8961,830 649.9%   
Net working cap to sales %33.9120.4 28.1%  
Current ratio x1.65.3 29.8%  
Inventory Days Days3649 73.8%  
Debtors Days Days19825 786.3%  
Net fixed assets Rs m9,86157 17,238.6%   
Share capital Rs m341141 242.1%   
"Free" reserves Rs m12,3319,056 136.2%   
Net worth Rs m16,1399,196 175.5%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14611,499 288.2%  
Interest coverage x1.6128.4 1.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 108.9%   
Return on assets %8.15.0 161.7%  
Return on equity %6.96.2 110.2%  
Return on capital %12.310.1 122.3%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,402129 3,415.4%   
Fx outflow Rs m3,1841,734 183.6%   
Net fx Rs m1,219-1,605 -75.9%   
CASH FLOW
From Operations Rs m2,437-380 -642.3%  
From Investments Rs m-6,2654,208 -148.9%  
From Financial Activity Rs m2,490-3,318 -75.0%  
Net Cashflow Rs m-1,337510 -262.1%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 2.0 215.0%  
FIIs % 5.5 1.6 343.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.5 34.9%  
Shareholders   10,665 41,647 25.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS